AU762894B2 - Use of replication-deficient adenoviral vector to boost CD8+ T cell immune response to antigen - Google Patents

Use of replication-deficient adenoviral vector to boost CD8+ T cell immune response to antigen Download PDF

Info

Publication number
AU762894B2
AU762894B2 AU73024/00A AU7302400A AU762894B2 AU 762894 B2 AU762894 B2 AU 762894B2 AU 73024/00 A AU73024/00 A AU 73024/00A AU 7302400 A AU7302400 A AU 7302400A AU 762894 B2 AU762894 B2 AU 762894B2
Authority
AU
Australia
Prior art keywords
antigen
epitope
administration
individual
boosting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU73024/00A
Other languages
English (en)
Other versions
AU7302400A (en
Inventor
Sarah Catherine Gilbert
Carolyn Mary Hannan
Adrian Vivian Sinton Hill
Joerg Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU762894(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of AU7302400A publication Critical patent/AU7302400A/en
Application granted granted Critical
Publication of AU762894B2 publication Critical patent/AU762894B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU73024/00A 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost CD8+ T cell immune response to antigen Ceased AU762894B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9922361.2A GB9922361D0 (en) 1999-09-21 1999-09-21 Generating an immune response to an antigen
GB9922361 1999-09-21
PCT/GB2000/003601 WO2001021201A2 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen

Publications (2)

Publication Number Publication Date
AU7302400A AU7302400A (en) 2001-04-24
AU762894B2 true AU762894B2 (en) 2003-07-10

Family

ID=10861351

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73024/00A Ceased AU762894B2 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost CD8+ T cell immune response to antigen

Country Status (12)

Country Link
EP (2) EP1612269A1 (enExample)
JP (1) JP2003509470A (enExample)
CN (1) CN1391609A (enExample)
AT (1) ATE295421T1 (enExample)
AU (1) AU762894B2 (enExample)
BR (1) BR0014138A (enExample)
CA (1) CA2384806A1 (enExample)
DE (1) DE60020136T2 (enExample)
DK (1) DK1214416T3 (enExample)
ES (1) ES2241653T3 (enExample)
GB (1) GB9922361D0 (enExample)
WO (1) WO2001021201A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
EP1200622A4 (en) 1999-07-06 2004-12-22 Merck & Co Inc HIV VACCINE FROM AN ADENOVIRUS CARRYING THE GAG GENE
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2003097087A1 (en) * 2002-05-20 2003-11-27 Japan Science And Technology Agency Bcg vaccine and utilization thereof
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
CN100410382C (zh) * 2006-08-18 2008-08-13 上海交通大学医学院 一种可诱生细胞免疫应答的共表达载体和真核表达载体
AU2007322075B2 (en) * 2006-11-17 2013-07-25 Genetronics, Inc. Methods of enhancing immune response using electroporation-assisted vaccination and boosting
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
JP5710254B2 (ja) * 2007-09-14 2015-04-30 アンスティテュ・パストゥールＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ 外来エピトープを含む組換え偽ウイルスの発現および分泌を可能とするポリヌクレオチド、それらの製造および使用
GB0823497D0 (en) * 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
PT2912183T (pt) * 2012-10-28 2020-06-05 Bavarian Nordic As Promotor pr13.5 para respostas robustas de células t e anticorpos
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
MX2022004484A (es) * 2019-10-16 2022-07-19 Cancer Research Tech Ltd Vector para el tratamiento de cancer.
US20230310591A1 (en) 2021-12-07 2023-10-05 Vaccitech (Uk) Limited Vaccine Boost Methods and Compositions
WO2024218165A1 (en) 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INT.J.CANCER,71, 1997, PG 300-307 *

Also Published As

Publication number Publication date
EP1612269A1 (en) 2006-01-04
BR0014138A (pt) 2002-05-21
EP1214416A2 (en) 2002-06-19
CN1391609A (zh) 2003-01-15
WO2001021201A2 (en) 2001-03-29
EP1214416B1 (en) 2005-05-11
DE60020136T2 (de) 2006-02-23
DK1214416T3 (da) 2005-08-29
WO2001021201A3 (en) 2001-10-18
AU7302400A (en) 2001-04-24
JP2003509470A (ja) 2003-03-11
DE60020136D1 (de) 2005-06-16
ES2241653T3 (es) 2005-11-01
ATE295421T1 (de) 2005-05-15
CA2384806A1 (en) 2001-03-29
GB9922361D0 (en) 1999-11-24

Similar Documents

Publication Publication Date Title
AU762894B2 (en) Use of replication-deficient adenoviral vector to boost CD8+ T cell immune response to antigen
Gilbert et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime–boost immunisation regimes
EP1335023B1 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
Webster et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
Gilbert et al. Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations
US20100322896A1 (en) Molecular adjuvant
US11065320B2 (en) Prime target
AU775973B2 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
AU2004203141B2 (en) Methods and reagents for vaccination which generate CD8 T cell immune response

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 15, NO 28, PAGE(S) 5860-5863 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 73024/00 AND 76320/00

FGA Letters patent sealed or granted (standard patent)